Vaccine

Merck’s ENFLONSIA (clesrovimab-cfor), a new monoclonal antibody for RSV prevention in infants under eight months, has received a positive recommendation from the CDC’s ACIP. Approved by the FDA, ENFLONSIA aims to protect against RSV lower respiratory tract disease, with ordering for the 2025-2026 season starting in July. The standardized dose provides rapid, lasting protection for a typical five-month RSV season, with potential accessibility via the Vaccines for Children Program.

SINOVAC Biotech is urging shareholders to vote against proposals to replace the board, citing its efforts to restore shareholder value, including dividend payments and a strategic realignment. The company launched www.VoteSinovac.com and filed an investor presentation with the SEC, highlighting the board’s commitment to maximize shareholder investment, defend against litigation from a dissenting investor group, and potentially relist on the Hong Kong Stock Exchange.